Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Operating Leases: 2020-2024

Historic Operating Leases for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $581,148.

  • SAB Biotherapeutics' Operating Leases rose 198.34% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 198.34%. This contributed to the annual value of $581,148 for FY2024, which is 8.59% down from last year.
  • SAB Biotherapeutics' Operating Leases amounted to $581,148 in FY2024, which was down 8.59% from $635,777 recorded in FY2023.
  • SAB Biotherapeutics' 5-year Operating Leases high stood at $2.8 million for FY2021, and its period low was $361,225 during FY2022.
  • Over the past 3 years, SAB Biotherapeutics' median Operating Leases value was $581,148 (recorded in 2024), while the average stood at $526,050.
  • As far as peak fluctuations go, SAB Biotherapeutics' Operating Leases tumbled by 87.08% in 2022, and later skyrocketed by 76.01% in 2023.
  • Yearly analysis of 5 years shows SAB Biotherapeutics' Operating Leases stood at $2.4 million in 2020, then grew by 17.82% to $2.8 million in 2021, then plummeted by 87.08% to $361,225 in 2022, then spiked by 76.01% to $635,777 in 2023, then declined by 8.59% to $581,148 in 2024.